期刊文献+

替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌肺炎的效果及对微生物清除率、28 d病死率的影响

Effect of Tigecycline Combined with Cefoperazone/Sulbactam on Pan-drug Resistant Acinetobacter Baumannii Pneumonia and Its Effect on Microbial Clearance and 28-day Mortality
下载PDF
导出
摘要 目的:探讨替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌肺炎的效果及对微生物清除率、28 d病死率的影响。方法:选取2015年6月—2018年6月我院收治的泛耐药鲍曼不动杆菌肺炎患者82例为研究对象,按随机数字表法分为对照组和观察组,各41例。对照组采用头孢哌酮/舒巴坦(3 g,q8 h)治疗,观察组在对照组基础上联合替加环素(50 mg,bid)治疗。比较两组临床疗效、病原菌清除率及28 d病死率。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05);治疗后观察组微生物总清除率高于对照组,28 d病死率低于对照组,差异有统计学意义(P<0.05)。结论:替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌肺炎的疗效明确,可在提高微生物清除率同时降低28 d病死率。 Objective:To investigate the effect of tigecycline combined with cefoperazone/sulbactam on pan-drug resistant acinetobacter Baumannii pneumonia and its effect on microbial clearance and 28-day mortality.Methods:82 patients with pan-drug resistant acinetobacter Baumanmi pneumonia admitted to our hospital from June 2015 to June 2018 were selected as subjects investigated,and they were randomly divided into a control group and an observation group,41 cases each.The patients in the control group were treated with cefoperazone/sulbactam(3 g,q8 h),and the patients in the observation group were further treated with tigecycline(50 mg,bid).The clinical efficacy,pathogen removal rate and 28-day mortality were compared between the two groups.Results:The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the total microbial clearance rate in the observation group was higher than that in the control group,and the 28-day mortality was lower than that in the control group,with statistically significant differences(P<0.05).Conclusion:Tigecycline combined with cefoperazone/sulbactam has a clear therapeutic effect on Pan-drug resistant acinetobacter Baumannii pneumonia,which can increase the microbial clearance and reduce the 28-day mortality.
作者 李静 岳恒君 Li Jing;Yue Heng-jun(Department of Critical Medicine,General Hospital of Yima Coal Industry Group Co.,Ltd.,Yima Henan 472300,China;Department of Respiratory Medicine,General Hospital of Yima Coal Industry Group Co.,Ltd.,Yima Henan 472300,China)
出处 《中国合理用药探索》 CAS 2019年第12期15-17,共3页 Chinese Journal of Rational Drug Use
关键词 泛耐药鲍曼不动杆菌 肺炎 替加环素 头孢哌酮/舒巴坦 Pan-drug Resistant Acinetobacter Baumannii Pneumonia Pneumonia Tigecycline Cefoperazone/Sulbactam
  • 相关文献

参考文献10

二级参考文献90

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:241
  • 2王勤鹰,余敏,顾勤,邓冰,姜嘟嘟,赵丽娟,王星,詹青.替加环素治疗重症卒中相关性肺炎3例报道[J].神经病学与神经康复学杂志,2013,10(4):196-198. 被引量:1
  • 3卫生部办公厅.多重耐药菌医院感染预防与控制技术指南(试行).2011-01-17.
  • 4American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare- associated pneumonia[J]. Am J Respir Crit Care Med, 2005, 171(4): 388-416.
  • 5Zavascki A P, Carvalhaes C G, Picoo R C, et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii:resistance mechanisms and implications for therapy[J]. Expert Rev Anti Infect Ther, 2010, 8(1): 71-93.
  • 6Karageorgopoulos D E, Kelesidis T, Kelesidis I, et al. Tigecycline for the treatment of multidrug- resistant(including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence[J]. J Antimicrob Chemother, 2008, 62(1): 45-55.
  • 7Guner R, Hasanoglu I, Keske S, et al. Outcomes in patients infected with carbapenem-resistant Acinetobacter baurnannii and treated with tigecycline alone or in combination therapy[J]. Infection, 201 I, 39(6): 515-518.
  • 8Gallagher J C, Rouse H M. Tigecycline for the treatment of Acinetobaeter infections: a case series[J]. Ann Pharmacother, 2008, 42(9): 1188- 1194.
  • 9Gordon N C, Wareham D W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline[J]. J Antimicrobial Chemother, 2009, 63(4): 775-780.
  • 10Shin J A, Chang Y S, Kim H J, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection[J]. Yonsei Med J, 2012, 53(5): 974-984.

共引文献1086

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部